Compare OFG & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | ARDX |
|---|---|---|
| Founded | 1964 | 2007 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | OFG | ARDX |
|---|---|---|
| Price | $42.12 | $6.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $43.40 | $12.95 |
| AVG Volume (30 Days) | 416.9K | ★ 4.0M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.14 | $22.44 |
| Revenue Next Year | $1.38 | $34.00 |
| P/E Ratio | $9.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $33.15 | $3.21 |
| 52 Week High | $46.11 | $8.40 |
| Indicator | OFG | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 42.01 |
| Support Level | $41.27 | $6.92 |
| Resistance Level | $42.53 | $7.43 |
| Average True Range (ATR) | 1.01 | 0.31 |
| MACD | 0.23 | -0.15 |
| Stochastic Oscillator | 85.51 | 7.30 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.